Galectin Therapeutics
GALT
60 hedge funds and large institutions have $36.2M invested in Galectin Therapeutics in 2018 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 21 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
2% more capital invested
Capital invested by funds: $35.5M → $36.2M (+$766K)
2.23% less ownership
Funds ownership: 14.78% → 12.54% (-2.2%)
13% less funds holding
Funds holding: 69 → 60 (-9)
27% less call options, than puts
Call options by funds: $2.91M | Put options by funds: $3.98M
43% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$1.43M |
| 2 |
FFA
First Foundation Advisors
Irvine,
California
|
+$1.35M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.24M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$520K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$501K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$1.39M |
| 2 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.05M |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$339K |
| 4 |
IG
ING Group
Amsterdam,
Netherlands
|
-$318K |
| 5 |
Renaissance Technologies
New York
|
-$237K |
GALT Hedge Fund Activity: Q3 2018 in Review
60 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2018, worth a combined $36.2M — up 2.2% from $35.5M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of GALT and 12 opened new positions — a net loss of 9 holders — while 12 trimmed existing stakes and 20 added.
The largest buyer was Invesco, opening a new position worth an estimated $1.43M. The largest seller was EAM Investors, exiting entirely with an estimated $1.39M sold.
- 60 institutional investors held Galectin Therapeutics (GALT) as of Q3 2018, down from 69 in Q2 2018.
- Funds reported $36.2M of Galectin Therapeutics stock for Q3 2018, up 2.2% quarter-over-quarter.
- 12 funds opened new Galectin Therapeutics positions in Q3 2018 and 21 closed out, a net change of -9 holders.
- The largest Galectin Therapeutics buyer in Q3 2018 was Invesco, an estimated $1.43M added.
- The largest Galectin Therapeutics seller in Q3 2018 was EAM Investors, an estimated $1.39M sold.
Based on aggregated 13F filings for Q3 2018.